Literature DB >> 23608658

Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.

Michel Azizi1, Anne Blanchard, Beny Charbit, Grégoire Wuerzner, Séverine Peyrard, Eric Ezan, Christian Funck-Brentano, Joël Ménard.   

Abstract

Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs. We compared the effect of contrasted sodium diets on the pharmacokinetics of single oral doses of 8 mg candesartan cilexetil, 160 mg valsartan, 10 mg ramipril, and 50 mg atenolol administered to 64 (16 per group) normotensive male subjects randomly assigned to sodium depletion (SD) or sodium repletion (SR) in a crossover study. Pharmacodynamic response was assessed as the increase in plasma renin concentration for renin-angiotensin system blockers and electrocardiographic changes in PR interval duration for atenolol. The area under the curve (AUC) for plasma candesartan and atenolol concentrations was significantly lower for SR than for SD (respective ratios of AUC0-∞: 0.74; [90% CI, 0.66-0.82] and 0.69 [90% CI, 0.54-0.88], respectively), indicating a lack of bioequivalence between SR and SD. SR did not affect the pharmacokinetics of valsartan or ramipril. The increase in plasma renin concentration with the 3 renin-angiotensin system blockers was 10 times lower during the SR than the SD period. In the multiple regression analysis, the AUC0-24 of plasma drug concentration explained <1% and 21% of the variance of the AUC0-24 of delta plasma renin concentration for candesartan (P=0.8882/P=0.0368) during the SR and SD periods, respectively. The atenolol-induced lengthening of PR interval was fully reversed by SR. Thus, sodium balance modulates the pharmacokinetics of candesartan cilexetil and atenolol, with measurable effects on the selected pharmacodynamic end points.

Entities:  

Keywords:  atenolol; candesartan; pharmacodynamics; pharmacokinetics; ramipril; sodium; valsartan

Mesh:

Substances:

Year:  2013        PMID: 23608658     DOI: 10.1161/HYPERTENSIONAHA.113.01196

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Difference in 24-hour urine sodium excretion between controlled and uncontrolled patients on antihypertensive drug treatment.

Authors:  Moo-Yong Rhee; Sang-Ho Jo; Ji-Hyun Kim; Kwang-Il Kim; Deuk-Young Nah; Sun-Woong Kim; Namyi Gu; Ki-Chul Sung; Kyung-Soon Hong; Eun-Joo Cho; Sim-Yeol Lee
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-27       Impact factor: 3.738

3.  Effects of high- vs low-dose native vitamin D on albuminuria and the renin-angiotensin-aldosterone system: a randomized pilot study.

Authors:  Thierry Krummel; Maxime Ingwiller; Nicolas Keller; Eric Prinz; Emmanuelle Charlin; Dorothée Bazin; Thierry Hannedouche
Journal:  Int Urol Nephrol       Date:  2021-07-20       Impact factor: 2.370

4.  The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.

Authors:  Namyi Gu; Joo-Youn Cho; Kwang-Hee Shin; In-Jin Jang; Moo-Yong Rhee
Journal:  Drug Des Devel Ther       Date:  2016-04-19       Impact factor: 4.162

5.  Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method.

Authors:  Ramkumar Dubey; Manik Ghosh
Journal:  Sci Pharm       Date:  2014-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.